PDCD1 and metastatic neoplasm: Checkpoint inhibitor immunotherapies targeting programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been shown to significantly improve the overall survival of patients with advanced stage metastatic disease.3